title: Setting the record straight on TIDE: a lost opportunity for patients with diabetes.
abstract: Much has been written regarding the recently discontinued Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) trial (ClinicalTrials.gov NCT00879970; Diabetologia 55: 36-45) and a variety of opinions have been advanced regarding its purpose, context and design (N Engl J Med 397: 959-964). As such, we deemed it appropriate to clarify TIDE's objectives, research questions and design and the clinical equipoise regarding its research questions.
authors.affiliation: Population Health Research Institute, McMaster University, 1280 Main Street West, HSC 3V51 Hamilton, ON, Canada L8S 4K1. zubin.punthakee@mcmaster.ca
authors.forename: Zubin
authors.initials: Z
authors.lastname: Punthakee
authors.forename: Jackie
authors.initials: J
authors.lastname: Bosch
authors.forename: Hertzel C
authors.initials: HC
authors.lastname: Gerstein
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014807:Vitamin D / Q000627:therapeutic use*
chemical_list: D045162:Thiazolidinediones; D014807:Vitamin D